

The generation of candidate for Relapsed and Refractory Acute Myeloid Leukemia to FLT3 inhibitors via direct STAT5/3 inhibition

JW C&C Research Laboratories
 C&C Research Laboratories

ONCOLOGY	Candidate
Product Type	Chemical – Small Molecule
Indication	Acute Myeloid Leukemia
Target	Signal Transducer and Activator of Transcription 5 and 3 (STAT5 and 3)
MoA(Mechanism of Action)	Direct binding to STAT5/3 ➔ Inhibition of STAT5/3 activation ➔ Cell growth inhibition and induction of apoptotic cell death
Competitiveness	<ul style="list-style-type: none"> • Novel first-in-class inhibitor by directly binding to STAT5/3 proteins • Strong anti-tumor effects against relapsed/refractory patients to AML SoC (FLT3i, BCL2i) which has highly unmet medical needs
Development Stage	Candidate
Route of Administration	Oral Administration